X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (761) 761
gastroenterology & hepatology (659) 659
male (474) 474
female (457) 457
adult (439) 439
middle aged (317) 317
crohn's disease (279) 279
inflammatory-bowel-disease (223) 223
crohns-disease (207) 207
inflammatory bowel disease (205) 205
ulcerative colitis (186) 186
adolescent (167) 167
ulcerative-colitis (159) 159
aged (155) 155
infliximab (153) 153
crohn disease - drug therapy (133) 133
treatment outcome (130) 130
gastroenterology and hepatology (113) 113
abridged index medicus (110) 110
risk factors (106) 106
inflammatory bowel diseases (98) 98
young adult (92) 92
crohns disease (87) 87
therapy (84) 84
pharmacology & pharmacy (79) 79
crohn disease - pathology (75) 75
remission (75) 75
severity of illness index (75) 75
care and treatment (72) 72
crohn disease - genetics (69) 69
follow-up studies (68) 68
remission induction (68) 68
child (67) 67
life sciences (67) 67
antibodies, monoclonal - therapeutic use (65) 65
time factors (65) 65
double-blind method (63) 63
patients (62) 62
colitis, ulcerative - drug therapy (61) 61
crohn disease - diagnosis (61) 61
surgery (60) 60
adalimumab (59) 59
clinical trials (59) 59
recurrence (59) 59
risk (59) 59
inflammatory bowel-disease (58) 58
retrospective studies (58) 58
maintenance therapy (57) 57
tumor necrosis factor-alpha - antagonists & inhibitors (57) 57
analysis (55) 55
endoscopy (55) 55
animals (54) 54
immunosuppressive agents - therapeutic use (54) 54
prospective studies (54) 54
crohn disease - complications (53) 53
crohn disease - immunology (53) 53
gastrointestinal agents - therapeutic use (53) 53
intestine (53) 53
azathioprine (51) 51
gastroenterology (51) 51
incidence (51) 51
crohn disease - epidemiology (50) 50
inflammation (50) 50
epidemiology (48) 48
case-control studies (47) 47
colitis (46) 46
crohn disease - surgery (46) 46
medicine, general & internal (46) 46
c-reactive protein (45) 45
gastrointestinal diseases (45) 45
inflammatory bowel diseases - drug therapy (45) 45
aged, 80 and over (44) 44
anti-inflammatory agents - therapeutic use (44) 44
diagnosis (44) 44
ibd (44) 44
management (44) 44
mice (44) 44
prevalence (44) 44
intestinal mucosa - pathology (43) 43
colitis, ulcerative - diagnosis (42) 42
efficacy (42) 42
prognosis (42) 42
induction (41) 41
quality of life (41) 41
research (41) 41
rheumatoid-arthritis (39) 39
association (38) 38
monoclonal antibodies (37) 37
immunology (36) 36
medical research (36) 36
crohn disease - microbiology (35) 35
crohn’s disease (35) 35
medical colleges (35) 35
antibodies, monoclonal, humanized - therapeutic use (34) 34
colon (34) 34
health aspects (34) 34
safety (34) 34
studies (34) 34
antibodies, monoclonal - adverse effects (33) 33
chemical sciences (33) 33
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Alimentary pharmacology & therapeutics, ISSN 0269-2813, 2016, Volume 43, Issue 3, pp. 317 - 333
Journal Article
by Duricova, Dana and Sarter, Hélène and Savoye, Guillaume and Leroyer, Ariane and Pariente, Benjamin and Armengol-Debeir, Laura and Bouguen, Guillaume and Ley, Delphine and Turck, Dominique and Templier, Carole and Buche, Sebastien and Peyrin-Biroulet, Laurent and Gower-Rousseau, Corinne and Fumery, Mathurin and Andre, J M and Antonietti, M and Aouakli, A and Armand, A and Aroichane, I and Assi, F and Aubet, J P and Auxenfants, E and Ayafi-Ramelot, F and Bankovski, D and Barbry, B and Bardoux, N and Baron, P and Baudet, A and Bazin, B and Bebahani, A and Becqwort, J P and Benet, V and Benali, H and Benguigui, C and Ben Soussan, E and Bental, A and Berkelmans, I and Bernet, J and Bernou, K and Bernou-Dron, C and Bertot, P and Bertiaux-Vandaële, N and Bertrand, V and Billoud, E and Biron, N and Bismuth, B and Bleuet, M and Blondel, F and Blondin, V and Bohon, P and Boniface, E and Bonnière, P and Bonvarlet, E and Bonvarlet, P and Boruchowicz, A and Bostvironnois, R and Boualit, M and Bouche, B and Boudaillez, C and Bourgeaux, C and Bourgeois, M and Bourguet, A and Bourienne, A and Branche, J and Bray, G and Brazier, F and Breban, P and Brihier, H and Brung-Lefebvre, V and Bulois, P and Burgiere, P and Butel, J and Canva, J Y and Canva-Delcambre, V and Capron, J P and Cardot, F and Carpentier, P and Cartier, E and Cassar, J F and Cassagnou, M and Castex, J F and Catala, P and Cattan, S and Catteau, S and Caujolle, B and Cayron, G and Chandelier, C and Chantre, M and Charles, J and Charneau, T and Chavance-Thelu, M and Chirita, D and Choteau, A and Claerbout, J F and Clergue, P Y and Coevoet, H and Cohen, G and Collet, R and Colombel, J F and Coopman, S and ... and Epimad Group
Inflammatory bowel diseases, ISSN 1536-4844, 2019, Volume 25, Issue 2, pp. 394 - 402
Abstract Background Extraintestinal manifestations (EIM) have been associated with more severe course of inflammatory bowel disease. The aim was to study the... 
Crohn′s disease | elderly | extra-intestinal manifestation | pediatric | Life Sciences | Human health and pathology | Hépatology and Gastroenterology
Journal Article
Alimentary Pharmacology & Therapeutics, ISSN 0269-2813, 07/2017, Volume 46, Issue 1, pp. 68 - 69
Linked ContentThis article is linked to Cholapranee et al paper. To view this article visit https://doi.org/10.1111/apt.14030. 
COMPARATIVE EFFICACY | CROHNS-DISEASE | ULCERATIVE-COLITIS | CLINICAL-TRIALS | PHARMACOLOGY & PHARMACY | GASTROENTEROLOGY & HEPATOLOGY | NETWORK METAANALYSIS | Biological Products | Inflammatory Bowel Diseases | Humans | Gastrointestinal diseases | Intestine | Inflammatory bowel diseases
Journal Article
Alimentary pharmacology & therapeutics, ISSN 0269-2813, 2017, Volume 45, Issue 1, pp. 50 - 62
Summary Background Adalimumab is approved for use in patients with moderate to severe Crohn's disease (CD) or ulcerative colitis (UC) who have not achieved... 
CLINICAL REMISSION | INFLAMMATORY-BOWEL-DISEASE | INCREASED RISK | COMBINATION THERAPY | AZATHIOPRINE | RANDOMIZED-TRIAL | PHARMACOLOGY & PHARMACY | MONOCLONAL-ANTIBODY | NECROSIS FACTOR THERAPY | INFLIXIMAB | GASTROENTEROLOGY & HEPATOLOGY | NONMELANOMA SKIN CANCERS | Double-Blind Method | Humans | Middle Aged | Immunologic Factors - administration & dosage | Male | Treatment Outcome | Colitis, Ulcerative - blood | Adalimumab - metabolism | Adalimumab - adverse effects | Adalimumab - administration & dosage | Anti-Inflammatory Agents - adverse effects | Colitis, Ulcerative - diagnosis | Crohn Disease - blood | Crohn Disease - drug therapy | Treatment Failure | Crohn Disease - diagnosis | Adult | Anti-Inflammatory Agents - administration & dosage | Anti-Inflammatory Agents - pharmacokinetics | Female | Remission Induction - methods | Colitis, Ulcerative - drug therapy | Drug Therapy, Combination | Complications and side effects | Care and treatment | Colitis | Analysis | Corticoids | Therapy | Effectiveness | Corticosteroids | Control methods | Immunomodulation | Clinical trials | Population studies | Pharmacology | Crohn's disease | Maintenance | Disease control | Patients | Incidence | Crohns disease | Inflammatory bowel disease | Studies | Randomization | Monoclonal antibodies | Remission | Safety | Pharmacokinetics | Immunomodulators | Ulcerative colitis | Original | Immunomodulators and Adalimumab for IBD
Journal Article